EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors

Jinhyuk Bhin, Mariana Paes Dias, Ewa Gogola, Frank Rolfs, Sander R Piersma, Roebi de Bruijn, Julian R de Ruiter, Bram van den Broek, Alexandra A Duarte, Wendy Sol, Ingrid van der Heijden, Christina Andronikou und 10 weitere

Cell Reports · 2023

DOI: 10.1016/j.celrep.2023.112538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2023. Verfasst von Jinhyuk Bhin und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands; Division of Molecular Carcino…. Hauptthemen laut MEDLINE: Neoplasms, Ovarian Neoplasms. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss Cancer League, Swiss National Science Foundation, KWF Kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRCA1 and BRCA2 both function in DNA double-strand break repair by homologous recombination (HR). Due to their HR defect, BRCA1/2-deficient cancers are sensitive to poly(ADP-ribose) polymerase inhibitors (PARPis), but they eventually acquire resistance. Preclinical studies yielded several PARPi resistance mechanisms that do not involve BRCA1/2 reactivation, but their relevance in the clinic remains elusive. To investigate which BRCA1/2-independent mechanisms drive spontaneous resistance in vivo, we combine molecular profiling with functional analysis of HR of matched PARPi-naive and PARPi-resistant mouse mammary tumors harboring large intragenic deletions that prevent reactivation of BRCA1/2. We observe restoration of HR in 62% of PARPi-resistant BRCA1-deficient tumors but none in the PARPi-resistant BRCA2-deficient tumors. Moreover, we find that 53BP1 loss is the prevalent resistance mechanism in HR-proficient BRCA1-deficient tumors, whereas resistance in BRCA2-deficient tumors is mainly induced by PARG loss. Furthermore, combined multi-omics analysis identifies additional genes and pathways potentially involved in modulating PARPi response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsOvarian NeoplasmsAnimalsMiceFemaleHumansBRCA1 ProteinBRCA2 ProteinMultiomicsPoly(ADP-ribose) Polymerase Inhibitors

Stichwörter der Autor:innen

BRCA1BRCA2CP: CancerPARP inhibitorbreast cancerhomologous recombinationmulti-omicstherapy resistance

Substanzen

BRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 ProteinPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Division of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, Oncode Institute, the Netherlands Cancer Institute, 1066CX Am…
  • Division of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.
  • Division of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands; OncoProteomics Laboratory, Department Medical Oncology, Amsterdam UMC, 1081HV Amsterdam, the Nether…
  • OncoProteomics Laboratory, Department Medical Oncology, Amsterdam UMC, 1081HV Amsterdam, the Netherlands.
  • Division of Cell Biology, Oncode Institute, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.
  • Division of Molecular Pathology, Oncode Institute, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical…

Förderung

  • Swiss Cancer League
  • Swiss National Science Foundation
  • KWF Kankerbestrijding
  • Wilhelm Sander Foundation
  • Oncode Institute
  • European Research Council
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Zitieren

APA

Bhin, J., Paes Dias, M., Gogola, E., Rolfs, F., Piersma, S. R., de Bruijn, R., de Ruiter, J. R., van den Broek, B., Duarte, A. A., Sol, W., van der Heijden, I., Andronikou, C., Kaiponen, T. S., Bakker, L., Lieftink, C., Morris, B., Beijersbergen, R. L., van de Ven, M., Jimenez, C. R., …, & Jonkers, J. (2023). Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors. Cell Reports. https://doi.org/10.1016/j.celrep.2023.112538

Vancouver

Bhin J, Paes Dias M, Gogola E, Rolfs F, Piersma SR, de Bruijn R, et al. Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors. Cell Reports. 2023. doi:10.1016/j.celrep.2023.112538

BibTeX
@article{Bhin2023,
  author = {Bhin, Jinhyuk and Paes Dias, Mariana and Gogola, Ewa and Rolfs, Frank and Piersma, Sander R and de Bruijn, Roebi and de Ruiter, Julian R and van den Broek, Bram and Duarte, Alexandra A and Sol, Wendy and van der Heijden, Ingrid and Andronikou, Christina and Kaiponen, Taina S and Bakker, Lara and Lieftink, Cor and Morris, Ben and Beijersbergen, Roderick L and van de Ven, Marieke and Jimenez, Connie R and Wessels, Lodewyk F A and Rottenberg, Sven and Jonkers, Jos},
  title = {Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors},
  journal = {Cell Reports},
  year = {2023},
  doi = {10.1016/j.celrep.2023.112538}
}
Kostenlos starten →